NCT03808558进行中（未招募）2 期
A Phase 2 Multi-center Pharmacodynamics Study of TVB-2640 in KRAS Mutant Non-small Cell Lung Carcinomas
David E Gerber4 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2019年9月11日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 18
- 试验地点
- 4
- 主要终点
- Disease control rate of TVB-2640
研究概览
简要总结
This is a prospective one-arm, two-stage phase 2 trial of TVB-2640 in KRAS mutant NSCLC patients. 13 patients will be treated with a minimum of 1 cycle of TVB-2640 therapy over 8 weeks.
详细描述
Patients with stable disease or partial/complete remissions will continue therapy.
The endpoints are response rate-RR, disease control rate-DCR, PFS-progression-free survival, CTCAEv5.0 toxicities, plasma lipid levels, collection of sebaceous secretion via Sebutape, and 11C-acetate PET tumor imaging.
In the first stage, 13 patients will be enrolled. If fewer than 2 patients achieve response, the study will be stopped. If 2 or more patients have a radiographic response, an additional 21 patients will be enrolled , for a total accrual of 34 patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Metastatic or advanced stage, histologically or cytologically confirmed NSCLC and molecular identification of oncogenic KRAS mutation.
- •KRAS mutant NSCLC must be refractory, relapsed, and previously treated with doublet chemotherapy and immune checkpoint inhibitor (unless there is a specific contraindication to checkpoint inhibitor).
- •Molecular characterization (tissue- or blood-based [ie, cell-free/circulating tumor DNA]) must have been performed and must have demonstrated an oncogenic KRAS mutation (e.g., exon 12, 13, 61, or 117 mutation detected by sequencing) by a CLIA-certified assay (source documentation required). KRAS mutations at other codons require review and approval by Study Chair.
- •Subjects' EGFR mutation and ALK gene rearrangement status must be known prior to study entry. Subjects with EGFR mutation or ALK gene rearrangement must have progressed after appropriate FDA-approved targeted therapy options prior to eligibility.
- •Patient has evidence of disease progression on most recent line of therapy.
- •Patient has measurable disease by RECIST v1.1 (Eisenhauer, 2009).
- •Age ≥ 18 years.
- •ECOG performance status of 0 or
- •Predicted life expectancy of >3 months.
- •Adequate organ and marrow function as defined below:
- •absolute neutrophil count ≥ 1,500/mcL
- •platelets ≥ 75,000/mcL
- •total bilirubin <2X institutional upper limit of normal
- •AST and ALT ≤5X institutional upper limit of normal
- •serum creatinine <1.5X institutional upper limit of normal
- •LVEF >50%
- •QTcF <470msec
- •Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- •A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
- •Has not undergone a hysterectomy or bilateral oophorectomy; or
- •Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
- •No significant ischemic heart disease or myocardial infarction within 6 months of first dose of TVB-2640 and with current adequate cardiac function as in 3.1.
- •Ability to understand and the willingness to sign a written informed consent.
排除标准
- •Patient is unable to swallow oral medications or has impairment of GI function or GI disease that may significantly alter drug absorption such as active inflammatory bowel disease, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome.
- •Patient has a history of risk factors for torsade de pointes such as uncontrolled heart failure, severe hypokalemia with potassium less than 3mM/L, history of long QT syndrome or require use during study participation of concomitant medications known to prolong QT/QTc interval.
- •Patients who require use of strong CYP3A4/5 agonists or inhibitors during study participation.
- •Patient has uncontrolled or severe intercurrent medical condition including uncontrolled brain metastases. Patients with stable brain metastases either treated or untreated, on a stable dose of steroids/anticonvulsants, with no dose increase within 4 weeks before the first dose of TVB-2640, and no anticipated dose change, are allowed.
- •Patient underwent major surgery within 4 weeks before the first dose of TVB-2640 or received cancer-directed therapy either chemotherapy, radiotherapy, hormonal therapy, biologic or immunotherapy, etc. or an investigational drug or device within 2 weeks (6 weeks for mitomycin C and nitrosoureas) or 5 half-lives of that agent, whichever is shorter before the first dose of TVB-
- •In addition, any drug- related toxicity, with the exception of alopecia, an endocrinopathy controlled with replacement therapy, or a clinically stable toxicity not expected to increase from study therapy (eg, cisplatin-associated ototoxicity) should have recovered to <Grade
- •If female, patient is pregnant or breast-feeding.
- •Patient has evidence of a serious active infection-infection requiring treatment with intravenous antibiotics.
- •Patient has known immunodeficiency virus-HIV or hepatitis B or C infection, as such patients may be at increased risk for toxicity due to concomitant treatment and disease-related symptoms may preclude accurate assessment of the safety of TVB-
- •Patient has an important medical illness or abnormal laboratory finding that, in the Investigator's opinion, would increase the risk of participating in this study.
- •Patients with prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational agent.
- •History of clinically significant dry eye (xerophthalmia) or other corneal abnormality or, if a contact lens wearer, does not agree to abstain from contact lens use from baseline through the last study drug dose.
- •Patient has a known allergy or hypersensitivity to components of TVB-
- •Patient has a prior history of hypersensitivity, drug/radiation-induced, or other immune-mediated pneumonitis.
研究组 & 干预措施
TVB-2640
Experimental
Patients will be administered TVB-2640 100mg/m2 orally once a day for 8 weeks.
干预措施: TVB-2640 (Drug)
结局指标
主要结局
Disease control rate of TVB-2640
时间窗: every 8 weeks through study completion, an average of 1 year
Determine Disease control rate of TVB-2640 in KRAS mutant NSCLC patients through RECIST and toxicity profile.
Response rate of TVB-2640
时间窗: every 8 weeks through study completion, an average of 1 year
Determine response rate of TVB-2640 in KRAS mutant NSCLC patients through RECIST and toxicity profile.
次要结局
- Establish the predictive value of 11C-acetate PET(Pretreatment and four weeks of treatment.)
- Safety profile of TVB-2640(Pretreatment and four weeks of treatment.)
- Mean change in sebaceous secretion of fatty acids(Pretreatment and four weeks of treatment.)
- Mean change in fasting plasma lipidomics(Pretreatment and four weeks of treatment.)
研究者
David E Gerber
PROFESSOR - Internal Medicine
University of Texas Southwestern Medical Center
研究点 (4)
Loading locations...
相似试验
已完成
2 期
Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast CancerBreast CancerTumorNCT00802945Nektar Therapeutics70
已完成
2 期
Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian CancerOvarian CancerTumorNCT00806156Nektar Therapeutics178
已完成
2 期
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal CancerColorectal CancerNCT00856375Nektar Therapeutics83
已完成
2 期
Early Phase 2 Clinical Study of TS-142 in Patients with Insomnia DisorderInsomnia DisorderNCT04573725Taisho Pharmaceutical Co., Ltd.24
终止
1 期
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor MalignanciesTriple Negative Breast CancerHead and Neck Squamous Cell CarcinomaColorectal CancerMelanomaMerkel Cell CarcinomaSarcomaRenal Cell CarcinomaNCT03435640Nektar Therapeutics64